{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/SNDX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T09:01:54.041Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9616,"canonical_name":"Syndax Pharmaceuticals Inc","cik":"0001395937","uei":null,"lei":null,"duns":null,"ticker":"SNDX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":31},"count":31,"timeline":[{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Syndax Pharmaceuticals Inc — 2026-08-07","url_slug":"/sec/cik-0001395937/schedule-13g/0000093751-26-000542","accession_number":"0000093751-26-000542","importance":55},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Syndax Pharmaceuticals Inc — 2026-08-04","url_slug":"/sec/cik-0001395937/10-q/0001193125-26-332750","accession_number":"0001193125-26-332750","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Syndax Pharmaceuticals Inc — 2026-08-04","url_slug":"/sec/cik-0001395937/8-k/0001193125-26-332736","accession_number":"0001193125-26-332736","importance":35},{"ts":"2026-07-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Syndax Pharmaceuticals Inc — 2026-07-14","url_slug":"/sec/cik-0001395937/8-k/0001193125-26-302608","accession_number":"0001193125-26-302608","importance":35},{"ts":"2026-07-09","kind":"sec.filing","form_type":"4","title":"4 — Syndax Pharmaceuticals Inc — 2026-07-09","url_slug":"/sec/cik-0001395937/4/0001193125-26-299803","accession_number":"0001193125-26-299803","importance":30},{"ts":"2026-07-08","kind":"sec.form144","reporter":"MICHAEL METZGER","title":"Director, Officer","shares":32375,"usd_value":752395,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001950047-26-006967","importance":40.150479},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Metzger Michael A","title":"Chief Executive Officer","shares":32375,"price_per_share":24.2402,"usd_value":784776,"security_title":"Common Stock","importance":35.784776475},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Syndax Pharmaceuticals Inc — 2026-07-08","url_slug":"/sec/cik-0001395937/144/0001950047-26-006967","accession_number":"0001950047-26-006967","importance":30},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Metzger Michael A","title":"Chief Executive Officer","shares":32375,"price_per_share":6.38,"usd_value":206553,"security_title":"Common Stock","importance":15.2065525},{"ts":"2026-06-12","kind":"sec.form144","reporter":"Botwood Nicholas A.J.","title":"Officer","shares":31235,"usd_value":566693,"security_title":"Common","approx_sale_date":"2026-06-12","accession_number":"0001959173-26-004618","importance":40.113338574},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Botwood Nicholas A.J.","title":"Head of R&D, CMO","shares":31235,"price_per_share":18.14,"usd_value":566603,"security_title":"Common Stock","importance":35.5666029},{"ts":"2026-06-12","kind":"sec.filing","form_type":"144","title":"144 — Syndax Pharmaceuticals Inc — 2026-06-12","url_slug":"/sec/cik-0001395937/144/0001959173-26-004618","accession_number":"0001959173-26-004618","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Syndax Pharmaceuticals Inc — 2026-06-12","url_slug":"/sec/cik-0001395937/4/0001193125-26-269694","accession_number":"0001193125-26-269694","importance":30},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Botwood Nicholas A.J.","title":"Head of R&D, CMO","shares":31235,"price_per_share":13.82,"usd_value":431668,"security_title":"Common Stock","importance":15.4316677},{"ts":"2026-06-11","kind":"sec.form144","reporter":"Botwood Nicholas A.J.","title":"Officer","shares":34280,"usd_value":609435,"security_title":"Common","approx_sale_date":"2026-06-11","accession_number":"0001959173-26-004566","importance":40.12188699},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Botwood Nicholas A.J.","title":"Head of R&D, CMO","shares":34280,"price_per_share":18,"usd_value":617040,"security_title":"Common Stock","importance":35.61704},{"ts":"2026-06-11","kind":"sec.filing","form_type":"144","title":"144 — Syndax Pharmaceuticals Inc — 2026-06-11","url_slug":"/sec/cik-0001395937/144/0001959173-26-004566","accession_number":"0001959173-26-004566","importance":30},{"ts":"2026-06-11","kind":"sec.insider.m","reporter":"Botwood Nicholas A.J.","title":"Head of R&D, CMO","shares":22515,"price_per_share":13.82,"usd_value":311157,"security_title":"Common Stock","importance":15.3111573},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Syndax Pharmaceuticals Inc — 2026-06-10","url_slug":"/sec/cik-0001395937/8-k/0001193125-26-265852","accession_number":"0001193125-26-265852","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Syndax Pharmaceuticals Inc — 2026-06-10","url_slug":"/sec/cik-0001395937/8-k/0001193125-26-266027","accession_number":"0001193125-26-266027","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Syndax Pharmaceuticals Inc — 2026-06-04","url_slug":"/sec/cik-0001395937/8-k/0001193125-26-256458","accession_number":"0001193125-26-256458","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Syndax Pharmaceuticals Inc — 2026-06-04","url_slug":"/sec/cik-0001395937/defa14a/0001193125-26-256557","accession_number":"0001193125-26-256557","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — Syndax Pharmaceuticals Inc — 2026-06-02","url_slug":"/sec/cik-0001395937/4/0001193125-26-253601","accession_number":"0001193125-26-253601","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — Syndax Pharmaceuticals Inc — 2026-06-02","url_slug":"/sec/cik-0001395937/4/0001193125-26-253603","accession_number":"0001193125-26-253603","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Metzger Michael A","title":"Officer, Director","shares":6847,"usd_value":130028,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001959173-26-004216","importance":40.02600559},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Goldan Keith A.","title":"Officer","shares":1177,"usd_value":22352,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001959173-26-004218","importance":40.004470364},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Metzger Michael A","title":"Chief Executive Officer","shares":6847,"price_per_share":18.99,"usd_value":130025,"security_title":"Common Stock","importance":35.13002453},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Goldan Keith A.","title":"Chief Financial Officer","shares":1177,"price_per_share":18.99,"usd_value":22351,"security_title":"Common Stock","importance":35.02235123},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Syndax Pharmaceuticals Inc — 2026-06-01","url_slug":"/sec/cik-0001395937/144/0001959173-26-004216","accession_number":"0001959173-26-004216","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Syndax Pharmaceuticals Inc — 2026-06-01","url_slug":"/sec/cik-0001395937/144/0001959173-26-004218","accession_number":"0001959173-26-004218","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Syndax Pharmaceuticals Inc — 2026-05-15","url_slug":"/sec/cik-0001395937/schedule-13g-a/0000919574-26-003472","accession_number":"0000919574-26-003472","importance":30}]}